Development
Recursion Pharmaceuticals, Inc.
RXRX
$5.49
$0.9220.13%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -61.75% | -53.89% | -17.03% | -16.70% | 11.46% |
| Total Depreciation and Amortization | 135.00% | 153.53% | 98.96% | 34.73% | 43.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 123.43% | 59.00% | 29.46% | 63.16% | 84.27% |
| Change in Net Operating Assets | -1,775.21% | 42.54% | -6.12% | -119.87% | 84.82% |
| Cash from Operations | -65.54% | -33.70% | -9.48% | -194.74% | 26.83% |
| Capital Expenditure | 74.09% | 90.98% | 75.92% | -19.18% | -78.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -99.35% | -100.00% | -100.11% | 100.00% |
| Cash from Investing | 68.82% | -100.65% | -141.56% | -103.73% | 84.73% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2,917.39% | -4.35% | -9.09% | -9.09% | -9.52% |
| Issuance of Common Stock | -44.76% | 2,179.19% | 41.67% | -7.60% | 3,758.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -45.23% | 2,200.60% | 41.94% | -7.77% | 3,779.24% |
| Foreign Exchange rate Adjustments | 140.39% | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -95.52% | -2,615.00% | -21.36% | -134.45% | 185.97% |